These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 16166800

  • 21. Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.
    Ito H, Ogata H, Yamamoto M, Takahashi K, Shishido K, Takahashi J, Taguchi S, Kinugasa E.
    Clin Nephrol; 2009 Jun; 71(6):660-8. PubMed ID: 19473635
    [Abstract] [Full Text] [Related]

  • 22. Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.
    Oyama Y, Kazama JJ, Omori K, Higuchi N, Kameda S, Yamamoto S, Ito Y, Maruyama H, Narita I, Gejyo F.
    Clin Exp Nephrol; 2005 Jun; 9(2):142-7. PubMed ID: 15980949
    [Abstract] [Full Text] [Related]

  • 23. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.
    Malberti F, Corradi B, Cosci P, Calliada F, Marcelli D, Imbasciati E.
    Am J Kidney Dis; 1996 Nov; 28(5):704-12. PubMed ID: 9158208
    [Abstract] [Full Text] [Related]

  • 24. Treatment of refractory secondary hyperparathyroidism with ethanol injection: the importance of glandular volume.
    Douthat WG, Orozco SE, de Arteaga J, Massari PU.
    Kidney Int Suppl; 2003 Jun; (85):S101-4. PubMed ID: 12753277
    [Abstract] [Full Text] [Related]

  • 25. Renoprotection following treatment of secondary hyperparathyroidism with percutaneous ethanol injection in pre-dialysis patients.
    Chen HH, Chen YC, Yeh JC.
    Nephron; 2002 Sep; 92(1):105-10. PubMed ID: 12187092
    [Abstract] [Full Text] [Related]

  • 26. Suppression of parathyroid hormone secretion in CAPD patients by intraperitoneal administration of Maxacalcitol.
    Murakami K, Miyachi H, Watanabe A, Kawamura N, Fujii M, Koide S, Murase M, Kushimoto H, Hasegawa M, Tomita M, Hiki Y, Sugiyama S.
    Clin Exp Nephrol; 2004 Jun; 8(2):134-8. PubMed ID: 15235930
    [Abstract] [Full Text] [Related]

  • 27. Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass.
    Chen CL, Chen NC, Liang HL, Hsu CY, Chou KJ, Fang HC, Lee PT.
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2784-92. PubMed ID: 25955225
    [Abstract] [Full Text] [Related]

  • 28. Role of the parathyroid gland vascularization index in predicting percutaneous ethanol injection efficacy in refractory uremic hyperparathyroidism.
    Chen HH, Lu KC, Lin CJ, Wu CJ.
    Nephron Clin Pract; 2011 Jul; 117(2):c120-6. PubMed ID: 20693813
    [Abstract] [Full Text] [Related]

  • 29. Percutaneous ethanol injection therapy in post-transplant patients with secondary hyperparathyroidism.
    Douthat WG, Orozco SE, Maino P, Cardozo G, de Arteaga J, de la Fuente J, Chiurchiu CR, Massari PU.
    Transpl Int; 2007 Dec; 20(12):1031-5. PubMed ID: 17883371
    [Abstract] [Full Text] [Related]

  • 30. Clinical features and hyperplastic patterns of parathyroid glands in hemodialysis patients with advanced secondary hyperparathyroidism refractory to maxacalcitol treatment and required parathyroidectomy.
    Tominaga Y, Matsuoka S, Sato T, Uno N, Goto N, Katayama A, Haba T, Kazuharu Uchida (Yagoto PTx Forum).
    Ther Apher Dial; 2007 Aug; 11(4):266-73. PubMed ID: 17661832
    [Abstract] [Full Text] [Related]

  • 31. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
    Greenbaum LA, Grenda R, Qiu P, Restaino I, Wojtak A, Paredes A, Benador N, Melnick JZ, Williams LA, Salusky IB.
    Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
    [Abstract] [Full Text] [Related]

  • 32. Long-term prognosis of parathyroid function after successful percutaneous ethanol injection therapy (PEIT) guided by color Doppler flow mapping in chronic dialysis patients.
    Kakuta T, Kunimatsu K, Tadaki F, Fujisaki T, Noguchi M, Abe Y, Sakai H, Kurokawa K, Saito A.
    Biomed Pharmacother; 2000 Jun; 54 Suppl 1():60s-65s. PubMed ID: 10914993
    [Abstract] [Full Text] [Related]

  • 33. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ.
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [Abstract] [Full Text] [Related]

  • 34. Effect of intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
    Liou HH, Chiang SS, Tsai SC, Chang CC, Wu SC, Shieh SD, Huang TP.
    Zhonghua Yi Xue Za Zhi (Taipei); 1994 Jun; 53(6):319-24. PubMed ID: 8087705
    [Abstract] [Full Text] [Related]

  • 35. [Percutaneous ethanol injections in the treatment of secondary hyperparathyroidism].
    Kuzdak K, Rybińska A, Białas M.
    Endokrynol Pol; 2005 Jun; 56(6):891-6. PubMed ID: 16821207
    [Abstract] [Full Text] [Related]

  • 36. Surgical verification of percutaneous maxacalcitol injection therapy on enlarged parathyroid glands in chronic dialysis patients.
    Yamamoto H, Katoh N, Takeyama H, Ikeda M, Yokoyama K, Shigematsu T, Kawaguchi Y, Hosoya T.
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii50-2. PubMed ID: 12771301
    [Abstract] [Full Text] [Related]

  • 37. Efficacy of direct injection of calcitriol into the parathyroid glands in uraemic patients with moderate to severe secondary hyperparathyroidism.
    Nakanishi S, Yano S, Nomura R, Tsukamoto T, Shimizu Y, Shin J, Fukagawa M.
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii47-9. PubMed ID: 12771300
    [Abstract] [Full Text] [Related]

  • 38. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
    Cooper K, Quarles D, Kubo Y, Tomlin H, Goodman W.
    Nephron Clin Pract; 2012 Jun; 121(3-4):c124-30. PubMed ID: 23208191
    [Abstract] [Full Text] [Related]

  • 39. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
    Liou HH, Chiang SS, Huang TP, Shieh SD, Akmal M.
    Miner Electrolyte Metab; 1994 Jun; 20(3):97-102. PubMed ID: 7816008
    [Abstract] [Full Text] [Related]

  • 40. The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites.
    Ando R, Naito S, Inagaki Y, Hata T, Ishida Y, Chida Y, Takayama M, Tachibana K, Ohtsuka M, Inoue A.
    Ther Apher Dial; 2005 Feb; 9(1):16-23. PubMed ID: 15828901
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.